Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508721 | 1.00 | BCL6 (1.00) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL23357584 | 0.95 | BCL6 (0.91) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30745252 | 0.95 | BCL6 (0.91) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30964545 | 0.95 | BCL6 (0.90) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30964552 | 0.94 | BCL6 (0.88) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30964547 | 0.94 | BCL6 (0.88) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL20569891 | 0.92 | BCL6 (0.86) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30745254 | 0.92 | BCL6 (0.86) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30964527 | 0.92 | BCL6 (0.85) | BCL6ADRB3HTR1DADORA1OPRM1 | |
| SCHEMBL30964521 | 0.92 | BCL6 (0.85) | BCL6ADRB3HTR1DADORA1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | claimed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | claimed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | claimed |
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| US-20220281931-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | claimed |
| WO-2021102283-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | WO | claimed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | claimed |
| CN-111163839-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2020-05-15 | — | — | CN | claimed |
| US-20260130997-A1 | METHODS AND COMPOSITIONS FOR ANTI-CD45 BASED NON-GENOTOXIC CONDITIONING | BEAM THERAPEUTICS INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260130907-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4713005-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD45 BASED NON-GENOTOXIC CONDITIONING | Beam Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2021074620-A1 | [1,4]OXAZEPINO[2,3-C]QUI NOLI NONE DERIVATIVES AS BLC6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-22 | — | — | WO | disclosed |
| CN-111163839-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | BCL6, BCL6B, BCL3 | BCL6 1/4885ADRB3 3587/4885HTR1D 1711/4885 |
| US-20260130907-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | BCL6, BCL6B, BCL9L | BCL6 1/4885ADRB3 1818/4885HTR1D 2621/4885 |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | BCL6 1/4885ADRB3 3749/4885HTR1D 2964/4885 |
| US-20260130997-A1 | METHODS AND COMPOSITIONS FOR ANTI-CD45 BASED NON-GENOTOXIC CONDITIONING | BCR, CD2BP2, NSUN2 | BCL6 674/4885ADRB3 3876/4885HTR1D 2254/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | BCL6 1/4885ADRB3 3596/4885HTR1D 514/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | BCL6 1/4885ADRB3 3749/4885HTR1D 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.